Advertisement

Hypoglycemia Following Inadvertent and Factitious Sulfonylurea Overdosages

  1. David C Klonoff, MD,
  2. Barbie J Barrett, MD,
  3. Martha S Nolte, MD,
  4. Robert M Cohen, MD and
  5. Richard Wyderski, MD
  1. Departments of Medicine, Peninsula Hospital Burlingame, California
  2. Departments of Emergency Medicine, Peninsula Hospital Cincinnati, Ohio
  3. Department of Medicine, University of California at San Francisco San Francisco, California
  4. Department of Medicine, University of Cincinnati Cincinnati, Ohio
  1. Address correspondence and reprint requests to David C. Klonoff, MD, Metabolic Research Unit, Room HSW-1141, University of California at San Francisco, San Francisco, CA 94143–0540.

Abstract

OBJECTIVE To recognize unreported sulfonylurea overdosages in hypoglycemic patients.

CASES We describe three patients with hypoglycemia due to inadvertent (in two patients) and factitious (in one patient) sulfonylurea overdosages. We review the world literature and summarize 43 previously published cases of inadvertently administered and 23 previously published cases of factitiously self-administered sulfonylurea overdosages with hypoglycemia.

RESULTS An inadvertently administered fulsonylurea overdosage usually occurred when a sulfonylurea was accidentally substituted for an intended medication with a similar generic or trade name. Features of the patients with a factitiously self-administered sulfonylurea overdosage included: 1) a history of the patient or patient's spouse having a medical job or sulfonylurea-treated diabetes mellitus; 2) an unusual affect or psychiatric history; 3) an abrupt onset of severe symptoms without previous milder symptoms; and 4) an absent hypoglycemic or hyperinsulinemic response to provocative testing. These features are not typical for an insulinoma.

CONCLUSIONS When a hypoglycemic patient denies antidiabetic medication use, we recommend sequentially performing: 1) a thorough pill inspection; 2) an interview for recently altered pill appearances; 3) a measurement of serum insulin and C-peptide levels during hypoglycemia; and 4) a blood or urine sulfonylurea screen. Discovery of an unreported sulfonylurea overdosage can eliminate the need to search for an insulinoma and prevent further overdosages from occurring.

  • Received August 12, 1993.
  • Revision received September 1, 1994.
  • Accepted September 1, 1994.
| Table of Contents
Advertisement